

## Special Issue

# Rabies Vaccines and Immunoglobulins

### Message from the Guest Editors

Rabies is a typically fatal but vaccine-preventable disease caused by infection with rabies virus (RABV) and other members of the *Lyssavirus* family. Rabies vaccines and immunoglobulins are essential for the prevention and control of the disease in human and animal populations. In this Special Issue, we invite submissions of original research or review articles to highlight the state of the art and future directions in the development of these biologics. Our scope encompasses use in humans or animals, for pre- or post-exposure prophylaxis or treatment. Topics of interest include (but are not limited to) safety, immunogenicity, and efficacy of current and next-generation rabies vaccines and immunoglobulins; delivery strategies for pre-exposure prophylaxis for domestic animal, wildlife or human populations; cost-effectiveness studies; thermostability; novel adjuvants; non-specific effects of vaccines; preclinical, clinical, or post-marketing studies of new products, regimens, or routes of administration; use of recombinant monoclonal antibodies for post-exposure prophylaxis or treatment.

---

### Guest Editors

Prof. Dr. Darryn Knobel

School of Veterinary Medicine, Ross University, Basseterre, St Kitts, Saint Kitts and Nevis

Dr. Carlos Palacios

Instituto de Ciencia y Tecnología Dr. César Milstein, CONICET-Fundación Pablo Cassará, Ciudad de Buenos Aires, Argentina

---

### Deadline for manuscript submissions

closed (31 October 2023)



## Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 7.7  
Indexed in PubMed



[mdpi.com/si/150559](https://mdpi.com/si/150559)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 7.7  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

---

### Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College  
Roosevelt, 4331 CB Middelburg, The Netherlands

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Infectious Diseases)

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).